SenzaGen
6.95
SEK
-0.71 %
SENZA
First North Stockholm
Medical Equipment & Services
Health Care
1 following
-0.71%
-2.11%
-5.44%
-2.11%
-25.11%
-4.53%
-3.47%
-45.7%
-69.58%
-83.55%
senzagen.com/home
Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.
Revenue
49.87M
EBIT %
-45.1 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SENZA
Daily low / high price
6.9 / 7.15
SEK
Market cap
205.05M SEK
Turnover
132.66K SEK
Volume
19K
Latest videos
Financial calendar
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Ålandsbanken i ägares ställe | 5.7 % | 5.7 % |
| Carl Borrebaeck | 5.7 % | 5.7 % |
| Malin Lindstedt | 5.5 % | 5.5 % |
| Caceis Bank, Germany Branch, W8IMY | 5.3 % | 5.3 % |
| Nordnet Pensionsförsäkring AB | 4.5 % | 4.5 % |
| Hans Westberg | 4.3 % | 4.3 % |
| Avanza Pension | 2.8 % | 2.8 % |
| Jonas Pålsson | 2.5 % | 2.5 % |
| Futur Pension | 2.5 % | 2.5 % |
ShowingAll content types
Penser Access & Future by Carnegie: SenzaGen: Ännu ett kvartal med hög tillväxttak - Q3 review
Penser Access & Future by Carnegie: SenzaGen: Intervju - Stark tillväxt i Q3
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools